Lineage Cell Therapeutics Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
77
- Stock Symbol
-
LCTX
- Investments
-
8
- Share Price
-
$0.77
- (As of Friday Closing)
Lineage Cell Therapeutics General Information
Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Contact Information
Website
www.lineagecell.comCorporate Office
- 2173 Salk Avenue
- Suite 200
- Carlsbad, CA 92008
- United States
Corporate Office
- 2173 Salk Avenue
- Suite 200
- Carlsbad, CA 92008
- United States
Lineage Cell Therapeutics Timeline
Lineage Cell Therapeutics Stock Performance
As of 20-Nov-2026, Lineage Cell Therapeutics’s stock price is $0.77. Its current market cap is $195M with 253M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.77 | $0.82 | $0.77 - $1.99 | $195M | 253M | 1.63M |
Lineage Cell Therapeutics Financials Summary
As of 30-Sep-2026, Lineage Cell Therapeutics has a trailing 12-month revenue of $10.8M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 192,056 | 345,538 | 79,406 | 151,026 |
| Revenue | 10,836 | 14,556 | 9,499 | 8,945 |
| EBITDA | (3,708) | (69,639) | (19,688) | (24,219) |
| Net Income | 1,753 | (63,533) | (18,609) | (21,486) |
| Total Assets | 100,110 | 112,584 | 113,218 | 101,019 |
| Total Debt | 2,029 | 2,419 | 2,514 | 2,952 |
Lineage Cell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lineage Cell Therapeutics Comparisons
Industry
Financing
Details
Lineage Cell Therapeutics Competitors (53)
One of Lineage Cell Therapeutics’s 53 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Orgenesis | Corporation | Germantown, MD |
Lineage Cell Therapeutics Patents
Lineage Cell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161581-A1 | Methods of characterizing cell populations for auditory conditions | Pending | 23-Jan-2025 | ||
| AU-2025212536-A1 | Combination methods comprising cell therapy and cochlear implant | Pending | 24-Jan-2024 | ||
| WO-2025160249-A1 | Combination methods comprising cell therapy and cochlear implant | Pending | 24-Jan-2024 | ||
| WO-2024102777-A2 | Compositions and method for expansion of embryonic stem cells | Inactive | 08-Nov-2022 | ||
| WO-2024102777-A3 | Compositions and method for expansion of embryonic stem cells | Inactive | 08-Nov-2022 | C12N5/0639 |
Lineage Cell Therapeutics Signals
Lineage Cell Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lineage Cell Therapeutics Investments & Acquisitions (8)
Lineage Cell Therapeutics’s most recent deal was a Merger/Acquisition with Neuroairmid Therapeutics for . The deal was made on 13-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neuroairmid Therapeutics | 13-Nov-2026 | Merger/Acquisition | Drug Delivery | ||
| Asterias Biotherapeutics | 11-Mar-2019 | Merger/Acquisition | Drug Discovery | ||
| Cell Cure Neurosciences | 18-Jun-2017 | Secondary Transaction - Private | Biotechnology | ||
| Cell Cure Neurosciences | 16-Feb-2016 | Secondary Transaction - Private | Biotechnology | ||
| Geron Corporation (Stem Cell Assets) | 01-Oct-2013 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Lineage Cell Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.87 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lineage Cell Therapeutics Exits (1)
Lineage Cell Therapeutics’s most recent exit was on 24-Mar-2011 from Recyte Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Recyte Therapeutics | 24-Mar-2011 | Completed |
|
Lineage Cell Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cell Cure Neurosciences | Jerusalem, Israel | 2005 | |
| Neuroairmid Therapeutics | Irvine, CA |
Lineage Cell Therapeutics FAQs
-
When was Lineage Cell Therapeutics founded?
Lineage Cell Therapeutics was founded in 1990.
-
Where is Lineage Cell Therapeutics headquartered?
Lineage Cell Therapeutics is headquartered in Carlsbad, CA.
-
What is the size of Lineage Cell Therapeutics?
Lineage Cell Therapeutics has 77 total employees.
-
What industry is Lineage Cell Therapeutics in?
Lineage Cell Therapeutics’s primary industry is Drug Discovery.
-
Is Lineage Cell Therapeutics a private or public company?
Lineage Cell Therapeutics is a Public company.
-
What is Lineage Cell Therapeutics’s stock symbol?
The ticker symbol for Lineage Cell Therapeutics is LCTX.
-
What is the current stock price of Lineage Cell Therapeutics?
As of 20-Nov-2026 the stock price of Lineage Cell Therapeutics is $0.77.
-
What is the current market cap of Lineage Cell Therapeutics?
The current market capitalization of Lineage Cell Therapeutics is $195M.
-
What is Lineage Cell Therapeutics’s current revenue?
The trailing twelve month revenue for Lineage Cell Therapeutics is $10.8M.
-
Who are Lineage Cell Therapeutics’s competitors?
Genetix Biotherapeutics, Allogene Therapeutics, Apellis Pharmaceuticals, Lisata Therapeutics, and Orgenesis are some of the 53 competitors of Lineage Cell Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process